Company logo

SONN - Sonnet BioTherapeutics Holdings, Inc.

NASDAQ -> Healthcare -> Biotechnology
Princeton, United States
Type: Equity

SONN price evolution
SONN
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 1 May 2023
Current assets
Cash $3.02 $2.27 $7.02 $11.39
Short term investments
Net receivables $0.19 $0.79 $0.75 $0.45
Inventory
Total current assets $4.62 $4.74 $9.63 $13.05
Long term investments
Property, plant & equipment $0.21 $0.23 $0.25 $0.27
Goodwill & intangible assets
Total noncurrent assets $0.71 $0.69 $0.4 $0.27
Total investments
Total assets $5.34 $5.43 $10.03 $13.31
Current liabilities
Accounts payable $1.66 $2.2 $3.02 $4.5
Deferred revenue $0.02 $0.06 $0.09
Short long term debt $0.08 $0.07 $0.07 $0.07
Total current liabilities $2.65 $5.52 $6.47 $7.77
Long term debt $0.11 $0.13 $0.15 $0.17
Total noncurrent liabilities $0.11 $0.13 $0.15 $0.17
Total debt $0.19 $0.2 $0.22 $0.24
Total liabilities $2.77 $5.66 $6.62 $7.94
Shareholders' equity
Retained earnings -$111.41 -$110.24 -$106.57 -$102.62
Other shareholder equity
Total shareholder equity $2.57 -$0.23 $3.42 $5.37
(in millions $) 31 Dec 2023 30 Oct 2022 31 Dec 2021 31 Dec 2020
Current assets
Cash $2.27 $3.05 $27.62 $7.35
Short term investments
Net receivables $0.79
Inventory
Total current assets $4.74 $5.41 $28.81 $7.64
Long term investments
Property, plant & equipment $0.23 $0.3 $0.18 $0.27
Goodwill & intangible assets
Total noncurrent assets $0.69 $0.42 $0.18 $0.36
Total investments
Total assets $5.43 $5.83 $28.99 $7.99
Current liabilities
Accounts payable $2.2 $4.75 $3.78 $2.06
Deferred revenue $0.02 $0.17 $0.52 $0.5
Short long term debt $0.07 $0.05 $0.1 $0.1
Total current liabilities $5.52 $8.16 $6.7 $4.72
Long term debt $0.13 $0.2 $0.03 $0.25
Total noncurrent liabilities $0.13 $0.2 $0.03 $0.25
Total debt $0.2 $0.26 $0.13 $0.35
Total liabilities $5.66 $8.37 $6.73 $4.97
Shareholders' equity
Retained earnings -$110.24 -$91.41 -$61.69 -$36.71
Other shareholder equity
Total shareholder equity -$0.23 -$2.54 $22.26 $3.02
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue $0.02 $0.04 $0.04 $0.04
Cost of revenue
Gross Profit $0.02 $0.04 $0.04 $0.04
Operating activities
Research & development $0.64 $1.84 $2.41 $3.82
Selling, general & administrative $0.65 $1.79 $1.54 $1.88
Total operating expenses $1.3 $3.64 $3.95 $5.7
Operating income -$1.28 -$3.6 -$3.92 -$5.66
Income from continuing operations
EBIT -$1.17 -$3.68 -$3.95 -$5.67
Income tax expense
Interest expense
Net income
Net income -$1.17 -$3.68 -$3.95 -$5.67
Income (for common shares) -$1.17 -$3.68 -$3.95 -$5.67
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $0.15 $0.35 $0.48
Cost of revenue
Gross Profit $0.15 $0.35 $0.48
Operating activities
Research & development $11.81 $21.44 $16.63 $9.88
Selling, general & administrative $7.13 $8.58 $8.94 $7.53
Total operating expenses $18.94 $30.02 $25.57 $24.24
Operating income -$18.79 -$29.67 -$25.09 -$24.24
Income from continuing operations
EBIT -$18.83 -$29.72 -$24.98 -$24.29
Income tax expense
Interest expense -$0.02
Net income
Net income -$18.83 -$29.72 -$24.98 -$24.27
Income (for common shares) -$18.83 -$29.72 -$24.98 -$65.6
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$1.17 -$3.68 -$3.95 -$5.67
Operating activities
Depreciation $0.02 $0.02 $0.02 $0.02
Business acquisitions & disposals -$0.44
Stock-based compensation $0.05 $0.05 $0.05 $0.06
Total cash flows from operations -$3.09 -$4.56 -$6.17 -$4.7
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.17 -$0.01 -$0.26
Financing activities
Dividends paid
Sale and purchase of stock $3.84 -$0.02 $1.82 $14.65
Net borrowings -$0
Total cash flows from financing $3.84 -$0.02 $1.81 $14.65
Effect of exchange rate
Change in cash and equivalents $0.75 -$4.75 -$4.37 $9.69
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$18.83 -$29.72 -$24.98 -$24.27
Operating activities
Depreciation $0.08 $0.09 $0.1 $0.06
Business acquisitions & disposals -$0.44 -$0.9
Stock-based compensation $0.25 $0.88 $1.38 $0.37
Total cash flows from operations -$21.34 -$27.69 -$22.55 -$15.61
Investing activities
Capital expenditures -$0 -$0.08
Investments
Total cash flows from investing -$0.44 -$0.9 -$0 -$0.08
Financing activities
Dividends paid
Sale and purchase of stock $21.01 $1.84 $42.85 $19.07
Net borrowings -$0 -$0.02 $0.13
Total cash flows from financing $21.01 $4.01 $42.83 $23.01
Effect of exchange rate
Change in cash and equivalents -$0.78 -$24.57 $20.27 $7.31
Fundamentals
Market cap $5.56M
Enterprise value $2.72M
Shares outstanding 3.07M
Revenue $129.18K
EBITDA -$14.38M
EBIT -$14.46M
Net Income -$14.46M
Revenue Q/Q -50.00%
Revenue Y/Y -49.81%
P/E ratio -0.38
EV/Sales 21.07
EV/EBITDA -0.19
EV/EBIT -0.19
P/S ratio 43.01
P/B ratio 2.16
Book/Share 0.84
Cash/Share 0.98
EPS -$4.71
ROA -169.54%
ROE -519.48%
Debt/Equity -25.03
Net debt/EBITDA 0.02
Current ratio 1.74
Quick ratio 1.74